Important Safety Information
Mesterolone is contraindicated in the presence of prostatic carcinoma, as androgens can stimulate the growth of an existing carcinoma. It is also contraindicated in previous or existing liver tumours, breast cancer, hypercalcaemia, and hypersensitivity to the active substance or excipients.
The diagnosis of hypogonadism in males requires full endocrinological assessment including clinical history, physical examination, and interpretation of serum testosterone, LH and FSH measurements. Prostate disease should be excluded prior to commencement, and regular examinations of the prostate should be carried out prophylactically.
Important
Non-Medical Use
Non-medical use of mesterolone falls outside approved indications. Official product information states that androgens are not suitable for enhancing muscular development in healthy individuals. Product purity does not establish that non-medical use is safe or appropriate.
Potential Adverse Effects
Frequent or persistent erections (priapism) may occur during treatment. If this happens, the dose should be discontinued to avoid injury to the penis. In older men, urinary obstruction may be precipitated. Increased libido may occur.
In rare cases, benign liver tumours and in even rarer cases malignant liver tumours leading to life-threatening intra-abdominal haemorrhage have been observed after the use of hormonal substances such as mesterolone. Severe upper abdominal complaints, liver enlargement, or signs of intra-abdominal haemorrhage should prompt consideration of liver tumour in the differential diagnosis.
Androgens may exacerbate conditions aggravated by fluid overload, such as cardiovascular disorders, renal impairment, hypertension, epilepsy, or migraine. Use in puberty may cause premature closure of the epiphyses and stop linear growth. Diabetes mellitus, androgen-sensitive polycythaemia, or sleep apnoea may be exacerbated.
Conditions Requiring Medical Evaluation
Mesterolone is not appropriate for everyone. Contraindications include prostatic carcinoma, previous or existing liver tumours, breast cancer, hypercalcaemia, and hypersensitivity to the active substance or excipients.
Prostate examination should be performed regularly during treatment to exclude prostatic carcinoma. Hepatic function monitoring is recommended in patients with hepatic impairment.
Monitoring During Therapy
Medically supervised mesterolone therapy may involve regular prostate examinations to exclude prostatic carcinoma, monitoring of hepatic function, and assessment of clinical response. Product information notes that androgens may influence laboratory test results, including thyroid hormone binding globulin levels.
Product Care
Storage & Handling
Store below 30°C in a cool, dry place, away from direct light and moisture. Keep out of reach and sight of children. Inspect tablets before use and do not use if they appear damaged or compromised.
Further Safety Information